Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT04794595
Recruiting Observational

Clinical Features and Outcomes of CBP Versus Non-CBP in Septic Children

NCT04794595 · tracked via the Priya Life Science China tracker
Sponsor
Children's Hospital of Fudan University
Phase
Observational
Started
2020-12-01
Last updated
2026-03-16

Condition(s) studied

SepsisChildren, Only

Investigational drug(s) / intervention(s)

CBP

CBP: continuous blood purification can prevent or treat fluid overload in children with septic shock or other sepsis-associated organ dysfunction who are unresponsive to fluid restriction and diuretic therapy management of septic AKI patients, particularly those with hemodynamic instability or fluid overload. Also, it can remove cytokines

Study summary

The effect of continuous blood purification (CBP) in children is unclear. Also, the timing of early application is still being explored. In this study, we need to explore the efficacy and the timing of application of CBP in children with sepsis or septic shock.

Eligibility

Sex
ALL
Min age
28 Days
Max age
18 Years
Healthy volunteers
No
Inclusion Criteria: * Age of 29d to 18 years old; * Children diagnosed with sepsis requiring blood purification. Exclusion Criteria: * with a history of a duration of PICU stay \<24 h * active bleeding, including cerebral hemorrhage

Primary outcome measure(s)

  • survival rate — 28 days after hospital discharge
    The survival rate of children in 28 days after hospital discharge

Trial sites (1)

FacilityCityRegionStatus
Children'S Hospital of Fudan University Shanghai Shanghai Municipality Recruiting

More Children's Hospital of Fudan University trials in China

Clinical Implementation of the Group Standard for Enteral Feeding Care in Critically Ill Children Starting soon
PK/PD of Ceftazidime Avitbatan Sodium in Children With Severe Infection Recruiting
YTS109 in Pediatric Relapsed/Refractory Autoimmune Diseases Starting soon
Development of an Early Warning Model for Intensive Care Unit-Acquired Weakness in Mechanically Ventilated Children Enrolling by invitation
Interactive Massage Intervention in Toddlers With Autism Spectrum Disorder Recruiting

Other trials for the same condition

PK/PD of Ceftazidime Avitbatan Sodium in Children With Severe Infection Recruiting
Effect of Xuebijing InjecTion on Outcomes in Sepsis Patients Under Real-World Conditions（EXIT-SEP REAL） Starting soon
Effect of Heart Rate Control With Ivabradine on Hemodynamic in Patients With Sepsis Recruiting
Blood DdPCR for Early Identification and Dynamic Surveillance of Pathogenic Bacteria in ICU Septic Patients: a Single-centre, Prospective, Observational Study Recruiting
Efficacy of Anisodamine Hydrobromide Combined With Low-molecular-weight Heparin in the Treatment of Patients With Sepsis Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04794595 on ClinicalTrials.gov ↗ ← All trials in China